Antibody evasion by the P.1 strain of SARS-CoV-2

Antibody evasion by the P.1 strain of SARS-CoV-2

Terminating the SARS-CoV-2 pandemic relies upon pan-global vaccination. Current vaccines elicit neutralizing antibody responses to the virus spike derived from early isolates. However, new strains have emerged with multiple mutations, including P.1 from Brazil, B.1.351 from South Africa, and B.1.1.7...

Cur síos iomlán

Sonraí bibleagrafaíochta
Príomhchruthaitheoirí:	Dejnirattisai, W, Zhou, D, Supasa, P, Liu, C, Mentzer, AJ, Ginn, HM, Zhao, Y, Duyvesteyn, HME, Tuekprakhon, A, Nutalai, R, Wang, B, López-Camacho, C, Slon-Campos, J, Walter, TS, Skelly, D, Costa Clemens, SA, Naveca, FG, Nascimento, V, Nascimento, F, Fernandes da Costa, C, Resende, PC, Pauvolid-Correa, A, Siqueira, MM, Dold, C, Levin, R, Dong, T, Pollard, AJ, Knight, JC, Crook, D, Lambe, T, Clutterbuck, E, Bibi, S, Flaxman, A, Bittaye, M, Belij-Rammerstorfer, S, Gilbert, SC, Carroll, MW, Klenerman, P, Barnes, E, Dunachie, SJ, Paterson, NG, Williams, MA, Hall, DR, Hulswit, RJG, Bowden, TA, Fry, EE, Mongkolsapaya, J, Ren, J, Stuart, DI, Screaton, GR
Formáid:	Journal article
Teanga:	English
Foilsithe / Cruthaithe:	Cell Press 2021

Míreanna comhchosúla

Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera
de réir: Zhou, D, et al.
Foilsithe / Cruthaithe: (2021)

Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum
de réir: Liu, C, et al.
Foilsithe / Cruthaithe: (2021)

Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera
de réir: Supasa, P, et al.
Foilsithe / Cruthaithe: (2021)

Potent cross-reactive antibodies following Omicron breakthrough in vaccinees
de réir: Nutalai, R, et al.
Foilsithe / Cruthaithe: (2022)

The antibody response to SARS-CoV-2 Beta underscores the antigenic distance to other variants
de réir: Liu, C, et al.
Foilsithe / Cruthaithe: (2021)

SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses
de réir: Dejnirattisai, W, et al.
Foilsithe / Cruthaithe: (2022)

Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum
de réir: Tuekprakhon, A, et al.
Foilsithe / Cruthaithe: (2022)

A delicate balance between antibody evasion and ACE2 affinity for Omicron BA.2.75
de réir: Huo, J, et al.
Foilsithe / Cruthaithe: (2022)

Integrative structural biology of viruses
de réir: Duyvesteyn, HME
Foilsithe / Cruthaithe: (2019)

Reduced neutralisation of SARS-CoV-2 omicron B.1.1.529 variant by post-immunisation serum
de réir: Dejnirattisai, W, et al.
Foilsithe / Cruthaithe: (2021)

The SARS-CoV-2 neutralizing antibody response to SD1 and its evasion by BA.2.86
de réir: Daming Zhou, et al.
Foilsithe / Cruthaithe: (2024-03-01)

Antigenic characterization of SARS-CoV-2 Omicron subvariant BA.4.6
de réir: Aiste Dijokaite-Guraliuc, et al.
Foilsithe / Cruthaithe: (2022-11-01)

Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002)
de réir: Flaxman, A, et al.
Foilsithe / Cruthaithe: (2021)

The alteration of NK cells phenotypes related to the functions and dengue disease outcomes
de réir: Napas Taechasan, et al.
Foilsithe / Cruthaithe: (2024-07-01)

Native-like SARS-CoV-2 spike glycoprotein expressed by ChAdOx1 nCoV-19/AZD1222 vaccine
de réir: Watanabe, Y, et al.
Foilsithe / Cruthaithe: (2021)

Generation of SARS-CoV-2 escape mutations by monoclonal antibody therapy
de réir: Ragonnet-Cronin, M, et al.
Foilsithe / Cruthaithe: (2023)

Fatal COVID-19 outcomes are associated with an antibody response targeting epitopes shared with endemic coronaviruses
de réir: McNaughton, AL, et al.
Foilsithe / Cruthaithe: (2022)

An exploratory analysis of the response to ChAdOx1 nCoV-19 (AZD1222) vaccine in males and females
de réir: Marchevsky, NG, et al.
Foilsithe / Cruthaithe: (2022)

Broad and strong memory CD4+ and CD8+ T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19
de réir: Peng, Y, et al.
Foilsithe / Cruthaithe: (2020)

Native-like SARS-CoV‑2 Spike Glycoprotein Expressed by ChAdOx1 nCoV-19/AZD1222 Vaccine
de réir: Yasunori Watanabe, et al.
Foilsithe / Cruthaithe: (2021-04-01)

Characterization of a potent and highly unusual minimally enhancing antibody directed against dengue virus
de réir: Renner, M, et al.
Foilsithe / Cruthaithe: (2018)

Human antibodies to the dengue virus E-dimer epitope have therapeutic activity against Zika virus infection
de réir: Fernandez, E, et al.
Foilsithe / Cruthaithe: (2017)

The antigenic anatomy of SARS-CoV-2 receptor binding domain
de réir: Dejnirattisai, W, et al.
Foilsithe / Cruthaithe: (2021)

Humoral responses against SARS-CoV-2 Omicron BA.2.11, BA.2.12.1 and BA.2.13 from vaccine and BA.1 serum
de réir: Jiandong Huo, et al.
Foilsithe / Cruthaithe: (2022-11-01)

Evolution of neurovirulent Zika virus
de réir: Screaton, G, et al.
Foilsithe / Cruthaithe: (2017)

Which dengue vaccine approach is the most promising, and should we be concerned about enhanced disease after vaccination? The challenges of a dengue vaccine
de réir: Screaton, G, et al.
Foilsithe / Cruthaithe: (2018)

A haemagglutination test for rapid detection of antibodies to SARS-CoV-2
de réir: Townsend, A, et al.
Foilsithe / Cruthaithe: (2021)

The early landscape of coronavirus disease 2019 vaccine development in the UK and rest of the world
de réir: Sharpe, HR, et al.
Foilsithe / Cruthaithe: (2020)

Distinct patterns of whole blood transcriptional responses are induced in mice following immunisation with adenoviral and poxviral vector vaccines encoding the same antigen
de réir: Sheerin, D, et al.
Foilsithe / Cruthaithe: (2021)

Generation of SARS-CoV-2 escape mutations by monoclonal antibody therapy
de réir: Manon Ragonnet-Cronin, et al.
Foilsithe / Cruthaithe: (2023-06-01)

Accelerating drug target inhibitor discovery with a deep generative foundation model
de réir: Chenthamarakshan, V, et al.
Foilsithe / Cruthaithe: (2023)

Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil
de réir: Faria, NR, et al.
Foilsithe / Cruthaithe: (2021)

Structural analysis of a dengue cross-reactive antibody complexed with envelope domain III reveals the molecular basis of cross-reactivity.
de réir: Midgley, C, et al.
Foilsithe / Cruthaithe: (2012)

Sensing of immature particles produced by dengue virus infected cells induces an antiviral response by plasmacytoid dendritic cells.
de réir: Elodie Décembre, et al.
Foilsithe / Cruthaithe: (2014-10-01)

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial
de réir: Folegatti, PM, et al.
Foilsithe / Cruthaithe: (2020)

Emerging variants develop total escape from potent monoclonal antibodies induced by BA.4/5 infection
de réir: Chang Liu, et al.
Foilsithe / Cruthaithe: (2024-04-01)

Covalently linked dengue virus envelope glycoprotein dimers reduce exposure of the immunodominant fusion loop epitope
de réir: Alexander Rouvinski, et al.
Foilsithe / Cruthaithe: (2017-05-01)

Humidity control as a strategy for lattice optimization applied to crystals of HLA-A*1101 complexed with variant peptides from dengue virus.
de réir: Chotiyarnwong, P, et al.
Foilsithe / Cruthaithe: (2007)

Potent neutralizing human monoclonal antibodies preferentially target mature dengue virus particles: implication for novel strategy of dengue vaccine
de réir: Tsai, W, et al.
Foilsithe / Cruthaithe: (2018)

Persistence of the immune response after two doses of ChAdOx1 nCov-19 (AZD1222): 1 year of follow up of two randomised controlled trials
de réir: Voysey, M, et al.
Foilsithe / Cruthaithe: (2023)